Boosted by Januvia, Merck bests expectations by a penny

It was Merck's ($MRK) diabetes franchise that saved the quarter for the second-largest pharmaceutical company in the U.S. Revenue from Januvia jumped 24% to $919 million, while sales of Janumet were u…
Read the full story: News